

DAFTAR PUSTAKA

1. Kemenkes RI. Profil Kesehatan Indonesia 2020. Kementrian Kesehatan Republik Indonesia. 2020.
2. Dirjen P2P. Laporan Program Penanggulangan Tuberkulosis Tahun 2021 [Internet]. Kemenkes RI. 2022. 1–147 hal. Tersedia pada: https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
3. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kemenkes RI [Internet]. 2023;1–156. Tersedia pada: https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
4. Dinkes Provinsi Jambi. Profil Kesehatan Provinsi Jambi. J Chem Inf Model. 2022;192.
5. Kemenkes P. Temukan TB Obati Sampai Sembuh Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. 2020. 6–7 hal.
6. Ardanari, Agustin R. TUBERKULOSIS. 1 ed. Yogyakarta: DEEPUBLISH; 2018.
7. Organization WH. Global Tuberculosis Report 2023. Vol. t/malaria/, January. 2023.
8. Kemenkes RI. Profil Kesehatan Indonesia 2019 [Internet]. Kementrian Kesehatan Republik Indonesia. 2019. 487 hal. Tersedia pada: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-indonesia-2019.pdf>
9. Ryansyah IC, Martilova S, Putri K, Sinaga ES. Faktor-Faktor Yang Memengaruhi Kepatuhan Pengobatan Pada Pasien TB. CoMPHI J Community Med Public Heal Indones J. 2023;3(3):178–83.
10. Ali MH, Alrasheedy AA, Kibuule D, Godman B, Hassali MA, Ali HMH. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev Anti Infect Ther [Internet]. 2019;17(11):927–37. Tersedia pada: <https://doi.org/10.1080/14787210.2019.1689818>
11. Liu Q, Zhu L, Shao Y, Song H, Li G, Zhou Y, et al. Rates and risk factors for drug resistance tuberculosis in Northeastern China. BMC Public Health. 2013;13(1).
12. Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A case-control study. BMC Public Health. 2018;18(1):91–6.
13. Kemenkes RI. Profil Kesehatan Indonesia 2018 [Internet]. Health Statistics.

2018. 207 hal. Tersedia pada: <https://www.kemkes.go.id/downloads/resources/download/pusdatin/profil-kesehatan-indonesia/profil-kesehatan-indonesia-2018.pdf>
14. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths : decision analysis. 2003;326(March):1–6.
 15. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus : a systematic review and meta-analysis of published studies. *Infect Dis Poverty* [Internet]. 2017;1–8. Tersedia pada: <http://dx.doi.org/10.1186/s40249-016-0214-x>
 16. Kurbatova E V, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. *Tuberculosis* [Internet]. 2017;92(5):397–403. Tersedia pada: <http://dx.doi.org/10.1016/j.tube.2012.06.003>
 17. Mashidayanti A, Nurlely N, Kartinah N. Faktor Risiko Yang Berpengaruh Pada Kejadian Tuberkulosis dengan Multidrug-Resistant Tuberculosis (MDR-TB) di RSUD Ulin Banjarmasin. *J Pharmascience*. 2020;7(2):139.
 18. Kementerian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran: Tata Laksana Tuberkulosis. 2020;282.
 19. Rahayu SR, Fauzi L, Maharani C. Kualitas Pelayanan Kesehatan Tuberkulosis melalui Quote Tb Light sebagai Upaya “ To End Tb .”
 20. Widyastuti Sakti, Erawati M, Utami RS, Dewi NS. Pengalaman Pasangan Hidup Dalam Mendampingi Pengobatan Pasien Multidrug Resistant Tuberculosis (MDR TB). *J Keperawatan dan Kesehat Masy STIKES Cendikia Utama Kudus*. 2021;Vol 10(1):41–50.
 21. WHO. WHO consolidated guidelines on tuberculosis (Drug-resistant tuberculosis treatment). 2022.
 22. Tola H, Holakouie-Naieni K, Mansournia MA, Yaseri M, Gamtesa DF, Tesfaye E, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: A 10-year retrospective cohort study. *BMJ Open*. 2021;11(8):1–9.
 23. Komalasari W, Indrawati F. Penatalaksanaan Program Pengendalian Tuberkulosis Multi Drug Resistant. *Higeia J Public Heal Res Dev* [Internet]. 2020;4(Special 4):887–97. Tersedia pada: <https://journal.unnes.ac.id/sju/index.php/higeia/article/view/37527>
 24. Noormarina Indraswari BS. Karakteristik Pasien Tuberkulosis Lost to Follow Up dari Empat RS di Kota Bandung. *J Epidemiol Kesehat Indones*. 2019;3(1):25–34.

25. Aviana F, Jati SP, Budiyantri RT. Systematic Review Pelaksanaan Programmatic Management of Drug-Resistant Tuberculosis Pada Pasien Tuberkulosis Resistan Obat. *J Kesehat Masy*. 2021;9(2):215–22.
26. Wati MR, Reviono, Putranto W, Sutanto YS, Harsini H. Pengaruh Faktor Risiko terhadap Waktu Timbulnya Efek Samping Kanamisin pada Tuberkulosis Resistan Obat. *Maj Kedokt Bandung*. 2018;50(2):86–92.
27. Wibowo A, Burhan E, Putra AC. Pola Resistansi Kuman Tuberkulosis dan Regimen Pengobatan Pada Pasien Tuberkulosis Resisten Obat Di Rumah Sakit Pusat Rujukan Respirasi Nasional Persahabatan Jakarta. *J Kedokt Univ Lampung*. 2021;5(1):1.
28. Al Qarni Bayan U. Karakteristik Pasien Tuberkulosis Resistan Obat di RSUD Dr. H. Chasan Boesoirie. *Kieraha Med J*. 2022;4(2):116–23.
29. Rintiswati. Resistensi Mycobacterium tuberculosis terhadap beberapa OAT. *Berkala Ilmu Kedokteran*. 2005;
30. Guglielmetti L, Barkane L, Dû D Le, Marigot-Outtandy D, Robert J, Veziris N, et al. Safety and efficacy of exposure to bedaquiline-delmamidine in multidrug-resistant tuberculosis: A case series from France and Latvia. *Eur Respir J*. 2018;51(3):30–3.
31. Kemenkes. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Pedoman Nas Pelayanan Kedokt Tata Laksana Tuberkulosis. 2020;(July):1–23.
32. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019.
33. Noveyani AE, Martini S. Evaluasi Program Pengendalian Tuberkulosis Paru Dengan Strategi DOTS Di Puskesmas Tanah Kalikedinding Surabaya. *J Berk Epidemiol*. 2014;2(2):251–62.
34. Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. *BMC Public Health*. 2019;19(1):1–11.
35. Xie Y, Han J, Yu W, Wu J, Li X, Chen H. Survival Analysis of Risk Factors for Mortality in a Cohort of Patients with Tuberculosis. *Can Respir J*. 2020;2020.
36. Wahyuningsih S, Zulkifli A, Arsin AA, Ansariadi, Nasir S, Muis M, et al. An analysis of risk factors for Multidrug Resistant Tuberculosis (MDR-TB): a hospital-based study. *J Public Heal Dev*. 2023;21(2):91–101.
37. Pratama IGBA, Darwinata AE, Hendrayana MA. Karakteristik Pasien Tuberkulosis Paru Dengan Multidrug Resistance Di Rsup Sanglah, Bali Tahun 2017 – 2018. *E-Jurnal Med Udayana*. 2021;10(4):63.
38. Cecile DI, S. AN, Joëlle D, Cedric N, Noemy C. Risk Factors Associated to

- Multidrug-Resistant Tuberculosis in Patients Attending the Deido District Hospital of Douala – Cameroon. *Int J Mycobacteriology*. 2022;11(4):356–63.
39. Wang J, Zhou M, Chen Z, Chen C, Wu G, Zuo Y, et al. Survival of patients with multidrug-resistant tuberculosis in central China: A retrospective cohort study. *Epidemiol Infect*. 2020;
 40. Rahmadani E, Sutrisna M. Hubungan Usia dan Jenis Kelamin dengan TB MDR. *SEHATRAKYAT (Jurnal Kesehatan Masyarakat)* [Internet]. 2022;1(4):370–6. Tersedia pada: <https://journal.y3a.org/index.php/sehatrakyat>
 41. Kang YA, Kim SY, Jo KW, Kim HJ, Park SK, Kim TH, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. *Respiration*. 2014;86(6):472–8.
 42. Habibi MR, Bakhtiar A, Indiasuti DN, Meliana RY. Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020. *J Ilm Univ Batanghari Jambi*. 2022;22(1):537.
 43. Kassa GM, Woldetsadik AT, Gelaw YA, Alemayehu TT, Tsegaye AT, Tamirat KS, et al. Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia; a retrospective follow-up study. *Epidemiol Infect*. 2020;
 44. Aristiana CD, Wartono M. Faktor-faktor yang mempengaruhi kejadian Multi Drug Resistance Tuberkulosis (MDR-TB). *J Biomedika dan Kesehatan*. 2018;1(1):65–74.
 45. Yu Q, Luo H, Hu S, Sun D, Nie Q, Yan J. The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study. *Front Cell Infect Microbiol*. 2023;13(May):1–10.
 46. Carter BB, Zhang Y, Zou H, Zhang C, Zhang X, Sheng R, et al. Survival analysis of patients with tuberculosis and risk factors for multidrug-resistant tuberculosis in Monrovia, Liberia. *PLoS One* [Internet]. 2021;16(4 April):1–12. Tersedia pada: <http://dx.doi.org/10.1371/journal.pone.0249474>
 47. Azalla CR, Maidar, Ismail N. Analisis Kualitas Hidup Penderita Tuberkulosis Paru terhadap Kepatuhan Pengobatan Tuberkulosis di Wilayah Kabupaten Pidie Jaya Tahun 2020. *J Aceh Med*. 2020;4(2):122–36.
 48. Ranzani OT, Rodrigues LC, Bombarda S, Minto CM, Waldman EA, Carvalho CRR. Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal study. *Lancet Infect Dis*. 2020;20(1):123–32.
 49. Ramos V, Campoy LT, Crispim JDA, Berra TZ, Alves LS, Alves YM, et al.

- Determinants of multidrug-resistant tuberculosis in S a Paulo — Brazil : a multilevel Bayesian analysis of factors associated with individual , community and access to health services. 2020;00(00):1–11.
50. Panford V, Kumah E, Kokuro C, Adoma PO, Baidoo MA, Fusheini A, et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region , Ghana : a retrospective , cross-sectional study. 2022;1–9.
 51. Setyaningrum TA, Carolia N, Ramadhian MR, Zakiah R, Farmakologi B, Kedokteran F, et al. Literature Review : Peran Pengawas Menelan Obat (PMO) Terhadap Pengobatan Penderita Tuberkulosis (TB) Literature Review : The Role of Drug Swallowing Supervisors (PMO) in the Treatment of Tuberculosis (TB) Patients. 2023;10(3):20–5.
 52. Wartonah, E R, Yarden N. Peran Pendamping Minum Obat (PMO) dalam Keteraturan Konsumsi Obat Klien TBC. JKEP. 2019;4 (1):54–61.
 53. Yusuf N, Hadi S, Yanifitri DB, Arliny Y. A case report : Drug-resistant tuberculosis with drug eruption skin due to second line anti tuberculosis drug and haemoptysis. J Kedokt Syiah Kuala. 2022;
 54. Studies C. A Conceptual Framework for Action on the Social Determinants of Health.
 55. Beke A. Determinants of Survival of Patients with Tuberculosis in in Developing Developing Countries Countries. 2018;
 56. Jannah BP dan L miftahul. Metodologi Penelitian Kuantitatif [Internet]. Vol. 3, PT Rajagrafindo Persada. 2016. 57 hal. Tersedia pada: <https://www.infodesign.org.br/infodesign/article/view/355%0Ahttp://www.abergo.org.br/revista/index.php/ae/article/view/731%0Ahttp://www.abergo.org.br/revista/index.php/ae/article/view/269%0Ahttp://www.abergo.org.br/revista/index.php/ae/article/view/106>
 57. Heriana C. Epidemiologi: Prinsip, Metode, dan Aplikasi dalam Kesehatan Masyarakat. 1 ed. Bandung: PT Refika Aditama; 2018.
 58. Patel S V, Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Kedar G, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India : A prospective study. J Infect Public Health [Internet]. 2015; Tersedia pada: <http://dx.doi.org/10.1016/j.jiph.2015.11.011>
 59. Massud A, Khan AH, Syed Sulaiman SA, Ahmad N, Shafqat M, Ming LC. Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan. PLoS One [Internet]. 2023;18(8 August):1–14. Tersedia pada: <http://dx.doi.org/10.1371/journal.pone.0287966>
 60. Pedersen OS, Butova T, Kapustnyk V, Miasoiedov V, Kuzhko M, Hryshchuk L, et al. Treatment outcomes and risk factors for an unsuccessful

- outcome among patients with highly drug-resistant tuberculosis in Ukraine. *Clin Microbiol Infect* [Internet]. 2024;30(3):360–7. Tersedia pada: <https://doi.org/10.1016/j.cmi.2023.12.001>
61. Kwon YS, Kim YH, Song JU, Jeon K, Song J, Ryu YJ, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: A multicenter retrospective cohort study. *J Korean Med Sci*. 2014;29(9):1226–31.
 62. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: Retrospective-prospective cohort study from 2004 to 2007. *Eurosurveillance* [Internet]. 2013;18(40):20601. Tersedia pada: <http://dx.doi.org/10.2807/1560-7917.ES2013.18.40.20601>
 63. Bogale L, Tsegaye T, Abdulkadir M, Akalu TY. Unfavorable treatment outcome and its predictors among patients with multidrug-resistance tuberculosis in southern ethiopia in 2014 to 2019: A multi-center retrospective follow-up study. *Infect Drug Resist*. 2021;14:1343–55.
 64. Sun Y, Harley D, Vally H, Sleigh A. Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China. *BMC Public Health*. 2015;15(1):1–8.
 65. Ayuningsih Z, Yunis T, Wahyono M. Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017. *Pro Heal J Ilm Kesehat* [Internet]. 2019;1(2):41–7. Tersedia pada: <http://jurnal.unw.ac.id/index.php/PJ/>
 66. Bajehson M, Musa BM, Gidado M, Nsa B, Sani U, Habibu AT, et al. Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria. *PLoS One*. 2019;14(11):1–10.
 67. El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: Multi-centric prospective study. *BMC Infect Dis*. 2019;19(1):1–7.
 68. Pradipta IS, Van'T Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JWC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015. *Antimicrob Resist Infect Control*. 2019;8(1):1–12.
 69. Khan I, Ahmad N, Khan S, Muhammad S, Ahmad Khan S, Ahmad I, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. *J Infect Public Health* [Internet]. 2019;12(6):809–15. Tersedia pada: <https://doi.org/10.1016/j.jiph.2019.04.009>
 70. Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. *PLoS One*. 2018;13(10):1–13.
 71. Abebe G, , Zegeye Bonsa WK. Risk Factors Associated to

- Multidrug-Resistant Tuberculosis in Patients Attending the Deido District Hospital of Douala – Cameroon. *Int J Mycobacteriology*. 2017;6(3):239–45.
72. Baluku JB, Nakazibwe B, Naloka J, Nabwana M, Mwanja S, Mulwana R, et al. Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study. *J Clin Tuberc Other Mycobact Dis* [Internet]. 2021;23:100221. Tersedia pada: <https://doi.org/10.1016/j.jctube.2021.100221>
 73. Kizito E, Musaazi J, Mutesasira K, Twinomugisha F, Namwanje H, Kiyemba T, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. *BMC Infect Dis*. 2021;21(1):1–7.
 74. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis : systematic review and meta-analysis. *Lancet Infect Dis* [Internet]. 2009;9(3):153–61. Tersedia pada: [http://dx.doi.org/10.1016/S1473-3099\(09\)70041-6](http://dx.doi.org/10.1016/S1473-3099(09)70041-6)
 75. Hidayat Y, Gunawan H. Hubungan Pengawas Menelan Obat (Pmo) Dengan Kepatuhan Minum Obat Penderita Tuberkulosis. *J Keperawatan 'Aisyiyah*. 2021;8(2):133–9.